The arrival of a 750mcg teriparatide injection in Australia has been somewhat restricted , with distribution primarily through specialist endocrinologists and designated treatment centers. Preliminary market uptake for this higher dosage remain confidential from the supplier , although reports suggest gradual adoption rates . Patient access is mana